NORWOOD, MA February 18, 2003 Cyclis Pharmaceuticals, Inc. today announced publication of laboratory studies demonstrating that an experimental anti-cancer agent, -lapachone, can selectively kill tumor cells while sparing healthy cells. The studies suggest a novel and fundamental therapeutic mechanism for potential cancer drugs that activate cellular pathways for selectively inducing death in cancer cells. Using this approach, called Activated Checkpoint TherapyTM
(ACT), Cyclis is discovering and developing small molecule anti-cancer drugs, the most advanced of which is CO-501. This product, which is based on the new findings, is expected to enter clinical trials in mid-2003.
The findings are published in the on-line edition of the Proceedings of the National Academy of Sciences.
"When DNA damage occurs in normal cells, a checkpoint pathway is activated that triggers apoptosis when that damage cannot be repaired," said Cyclis Vice President of Research Dr. Chiang J. Li, senior author of the paper. "In cancer cells these pathways are defective, leading to uncontrolled growth. These studies strongly suggest that one such pathway, involving the E2F1 protein, can be turned on with small molecule drugs, leading to selective killing of cancer cells."
"This research details one example of how our ACTTM platform works at the molecular level," said Cyclis President and CEO, Dr. Samuel K. Ackerman. "We have applied this platform successfully with our initial drug candidates. This approach also opens the door to additional drug discovery for a wide range of cancers by applying knowledge of this unique mechanism of action to multiple drug targets of the checkpoint system."
In these studies, the researchers compared the effects of -lapachone on human cancer cell and normal cell survival. They demonstrated that the compound selectively induces apoptosis in the tumor cells, but not in normal cells. They furtPage: 1 2 Related biology news :1
Contact: Shannon Altimari
Feinstein Kean Healthcare
. Warren Pharmaceuticals publishes results of preclinical evaluation2
. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals3
. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus4
. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage5
. Cubist Pharmaceuticals Describes New VITA Technology For Enabling Genomics For Drug Discovery6
. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway7
. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents8
. Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure9
. Pharmaceuticals Manufactured In Insect Larvae10
. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere11
. Scientists question reports of massive ant supercolonies in California and Europe